Actinium Pharmaceuticals
Feb 21, 2023
Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results
Actinium Announces Positive Full Data Results From the Pivotal Phase III SIERRA Trial Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced positive primary and secondary endpoint results from its pivotal Phase III SIERRA trial of Iomab-B in patients aged 55 and older...
Read More...
Sep 03, 2019
Helsinn out licenses Pracinostat in South America
Helsinn Group grants exclusive licensing rights to Blanver and Varifarma for its leading drug Pracinostat in South America. Helsinn is a Swiss biopharmaceutical company committed to producing the best solutions aimed at improving the quality of life for people with cancer. Under the terms of the agreements, ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
